Canada’s cannabis growers’ stocks traded in the U.S. market have been marching vigorously up since 2018 Farm Bill had made hemp, and thus CBD oil, legal across all of the U.S. states.
This news was followed by Canopy Growth’s (NYSE:CGC) announcement of its having received a license by the state of New York to grow and process hemp and being set to further spread its roots outside Canada, planning to invest somewhere between $100 million and $150 million into its New York-based operations.
Meanwhile, Aurora Cannabis’ CCO said the cannabis grower will unveil a plan to produce hemp-derived CBD for the U.S. market in the next few months.
Contrastingly, Tilray has stood out negatively, as it slid down by about 10% after the IPO lockup had expired. But on the positive side, Tilray will become the preferred supplier for CBD products for Authentic Brands, which might bolster up the cannabis sector’s heavyweight’s stock prices.
Financial scouts predict that the cannabis sector stocks are set to grow in the days to come, given the bright U.S. cannabis market outlook. Specifically, Canopy Growth and Tilray (NASDAQ:TLRY) are likely to trade at $44-$45 and $78-$79, respectively. And Aurora Cannabis’, Aphria’s (TO:APHA) and Сronos Group’s (NASDAQ:CRON) stock’s respective prices are expected to range $7-$7.5, $7.5-$8, and $16-$17.
Ivan Marchena, Libertex Analyst